These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39053890)

  • 1. Brexpiprazole for Agitation Associated With Dementia Due to Alzheimer's Disease.
    Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
    J Am Med Dir Assoc; 2024 Oct; 25(10):105173. PubMed ID: 39053890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.
    Grossberg GT; Kohegyi E; Mergel V; Josiassen MK; Meulien D; Hobart M; Slomkowski M; Baker RA; McQuade RD; Cummings JL
    Am J Geriatr Psychiatry; 2020 Apr; 28(4):383-400. PubMed ID: 31708380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's disease: a meta-analysis of randomized controlled trials.
    Marinheiro G; Dantas JM; Mutarelli A; Menegaz de Almeida A; Monteiro GA; Zerlotto DS; Telles JPM
    Neurol Sci; 2024 Oct; 45(10):4679-4686. PubMed ID: 38763935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C; Schatzberg AF
    Psychopharmacol Bull; 2024 Jul; 54(3):8-59. PubMed ID: 38993656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brexpiprazole (Rexulti) for agitation in Alzheimer's dementia.
    Med Lett Drugs Ther; 2023 Jun; 65(1679):99-101. PubMed ID: 37339089
    [No Abstract]   [Full Text] [Related]  

  • 6. New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.
    Caraci F; Santagati M; Caruso G; Cannavò D; Leggio GM; Salomone S; Drago F
    F1000Res; 2020; 9():. PubMed ID: 32695312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brexpiprazole for the Treatment of Schizophrenia: A Review of this Novel Serotonin-Dopamine Activity Modulator.
    McEvoy J; Citrome L
    Clin Schizophr Relat Psychoses; 2016; 9(4):177-86. PubMed ID: 26757416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brexpiprazole for the Treatment of Agitation in Alzheimer Dementia: A Randomized Clinical Trial.
    Lee D; Slomkowski M; Hefting N; Chen D; Larsen KG; Kohegyi E; Hobart M; Cummings JL; Grossberg GT
    JAMA Neurol; 2023 Dec; 80(12):1307-1316. PubMed ID: 37930669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 2023 update on the advancements in the treatment of agitation in Alzheimer's disease.
    Lee D; Clark ED; Antonsdottir IM; Porsteinsson AP
    Expert Opin Pharmacother; 2023 Apr; 24(6):691-703. PubMed ID: 36958727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease.
    Zhong K; Cummings J
    Expert Rev Neurother; 2024 Sep; ():1-9. PubMed ID: 39344050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brexpiprazole for the treatment of schizophrenia.
    Hsu WY; Lane HY; Lin CH
    Expert Opin Pharmacother; 2017 Feb; 18(2):217-223. PubMed ID: 27997809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on the advancements in the treatment of agitation in Alzheimer's disease.
    Porsteinsson AP; Antonsdottir IM
    Expert Opin Pharmacother; 2017 Apr; 18(6):611-620. PubMed ID: 28300462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.
    Panza F; Solfrizzi V; Seripa D; Imbimbo BP; Santamato A; Lozupone M; Prete C; Greco A; Pilotto A; Logroscino G
    Expert Opin Pharmacother; 2015; 16(17):2581-8. PubMed ID: 26389682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brexpiprazole in the treatment of schizophrenia and agitation in Alzheimer's disease.
    Stummer L; Markovic M; Maroney M
    Neurodegener Dis Manag; 2020 Aug; 10(4):205-217. PubMed ID: 32618483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brexpiprazole: A Review in Schizophrenia.
    Frampton JE
    Drugs; 2019 Feb; 79(2):189-200. PubMed ID: 30671869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of neuropsychiatric symptoms in dementia.
    Devanand DP
    Curr Opin Neurol; 2023 Oct; 36(5):498-503. PubMed ID: 37639488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancements in the treatment of agitation in Alzheimer's disease.
    Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP
    Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brexpiprazole: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2016 Apr; 30(4):335-42. PubMed ID: 27023789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Other Antidepressants.
    Schwasinger-Schmidt TE; Macaluso M
    Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of short- and long-term tolerability and safety of brexpiprazole in patients with schizophrenia.
    Kane JM; Skuban A; Hobart M; Ouyang J; Weiller E; Weiss C; Correll CU
    Schizophr Res; 2016 Jul; 174(1-3):93-98. PubMed ID: 27188270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.